Advances in 211At production at Texas A&M University

S.J. Yennello; L.A McIntosh; J.D. Burns; E.E. Tereshatov; G. Tabacaru; L. McCann; S. Schultz; K. Lofton; A. Abbott; G. Avila; M. Berko; E. Engelthaler; K. Hagel; A. Hannaman; B. Harvey; A. Hood; M. McCarthy; A.B. McIntosh; M. Sorensen; Z Tobin; A. Vonder Haar

doi:10.1051/epjconf/202125203002

All issues

Volume 252 (2021)

EPJ Web Conf., 252 (2021) 03002

Abstract

Open Access

Issue		EPJ Web Conf. Volume 252, 2021 HINPw6 – Hellenic Institute of Nuclear Physics; 6^th International Workshop; Perspectives on Nuclear Physics; From Fundamentals to Applications


Article Number		03002
Number of page(s)		5
Section		Advances in Nuclear Facilities
DOI		https://doi.org/10.1051/epjconf/202125203002
Published online		10 September 2021

EPJ Web of Conferences 252, 03002 (2021)
https://doi.org/10.1051/epjconf/202125203002

Advances in ²¹¹At production at Texas A&M University

S.J. Yennello¹^,2^*, L.A McIntosh¹, J.D. Burns³, E.E. Tereshatov¹, G. Tabacaru¹, L. McCann¹^,2, S. Schultz¹^,2, K. Lofton¹^,2, A. Abbott¹, G. Avila¹, M. Berko¹^,4, E. Engelthaler¹^,5, K. Hagel¹, A. Hannaman¹, B. Harvey¹, A. Hood¹, M. McCarthy¹, A.B. McIntosh¹, M. Sorensen¹, Z Tobin¹ and A. Vonder Haar¹

¹ Cyclotron Institute, Texas A&M University, College Station, TX, USA
² Department of Chemistry, Texas A&M University, College Station, TX, USA
³ Nuclear Engineering and Science Center, Texas A&M University, College Station, TX, USA
⁴ New Jersey Institute of Technology, Newark, NJ, USA
⁵ University of Dallas, Dallas, TX, USA

^* e-mail: yennello@tamu.edu

Published online: 10 September 2021

Abstract

Alpha emitting radionuclides with medically relevant half-lives are interesting for treatment of tumors and other diseases because they deposit large amounts of energy close to the location of the radioisotope. Researchers at the Cyclotron Institute at Texas A&M University are developing a program to produce ²¹¹At, an alpha emitter with a medically relevant half-life. The properties of ²¹¹At make it a great candidate for targeted alpha therapy for cancer due to its short half-life (7.2 h). Astatine-211 has now been produced multiple times and reliability of this process is being improved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.